Chimeric Antigen Receptor T Cells Directed Against CD19 for Relapsed/Refractory CLL and ALL


Chimeric Antigen Receptor T Cells Directed Against CD19 for Relapsed/Refractory CLL and ALL
Slides from a presentation at ASH 2012 and transcribed comments from a recent interview with Brad S Kahl, MD (1/14/13)
Porter D et al. Chimeric antigen receptor T cells directed against CD19 induce durable responses and transient cytokine release syndrome in relapsed, refractory CLL and ALL. Proc ASH 2012;Abstract 717.

Dr Kahl is Skoronski Chair of Lymphoma Research and Associate Professor at the University of Wisconsin School of Medicine and Public Health and Associate Director for Clinical Research at UW Carbone Cancer Center in Madison, Wisconsin.